Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition

22 September 2026 · By · Wire by Fusion42

Published

22 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 22 September 2026 · Fusion42 review

Celldex's monoclonal antibody barzolvolimab achieved positive results in two phase 3 trials for treatment-refractory chronic spontaneous urticaria, meeting primary and secondary endpoints. The company plans to seek FDA approval in 2027 following these successful 52-week studies.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You are seeing a path open to compete with Xolair in hard-to-treat chronic hives if you develop mast cell biology drugs. Launch preparations should start now to reposition against existing leaders.

◆ Coverage

1 source · 22 Sep 2026

◆ Related on Wire

◆ Topics

Biotechmonoclonal-antibodyphase-3clinical-trialschronic-urticariadrug-approval